Vanicoside B

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Vanicoside B is a natural product for research related to life sciences.

Vanicoside B is a natural product for research related to life sciences.

Western Blot Analysis Cell Line:MDA-MB-231 cells and HCC38 cells Concentration:0, 2.5, 5, 10 μM Incubation Time:48 hours Result:Increased cleaved PARP, and p27 protein expressions, but decreased Skp2 protein level.Suppressed CDK8 target genes and the expression of EMT-associated proteins.Suppressed the expression of the cell proliferation marker Ki-67 in tumor tissues, also significantly suppressed the expressions of p-STAT1 (S727) and AXL.Cell Cycle Analysis Cell Line:MDA-MB-231 cells and HCC38 cells Concentration:0, 2.5, 5, 10 μMIncubation Time:72 hours Result:Inhibited cell cycle at sub-G1 phase.

Animal Model:MDA-MB-231 cell-implanted xenograft mouse modelDosage:5 mg/kg, 20 mg/kg Administration:Intraperitoneal injection; 3 times per week over 4 weeks Result:Significantly reduced tumor volumes at 5 mg/kg and 20 mg/kg by 53.85% and 65.72%, respectively.

——

Others

Other Targets

——

——

——

155179-21-8

956.9

C49H48O20

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years